Key result
Switching to prasugrel safely resolves ticagrelor-induced cutaneous hypersensitivity within 48 hours post-PCI.
Why the study?
Ticagrelor is widely used post-PCI in acute coronary syndrome, but hypersensitivity reactions to it are rarely reported.
Does switching from ticagrelor to prasugrel safely resolve ticagrelor-induced cutaneous hypersensitivity in a patient with acute coronary syndrome post-PCI?
Case Report (n=1)
No
Does switching from ticagrelor to prasugrel safely resolve ticagrelor-induced cutaneous hypersensitivity in a patient with acute coronary syndrome post-PCI?
Switching from ticagrelor to prasugrel is a safe and effective strategy for managing ticagrelor-induced cutaneous hypersensitivity in patients with acute coronary syndrome post-PCI.
Ticagrelor hypersensitivity warrants clinical vigilance in ACS; this case extends sparse reports but should not yet change practice.
Objective: Ticagrelor is a potent oral P2Y12 receptor inhibitor widely used as part of dual antiplatelet therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI).Although generally well tolerated, hypersensitivity reactions to ticagrelor are rarely reported.Case presentation: We describe a case of a 56-year-old male with acute coronary syndrome who developed generalized pruritus, urticarial rash, and angioedema following initiation of ticagrelor after intravascular ultrasoundguided PCI.Prompt recognition, exclusion of infective causes, and substitution with prasugrel led to complete symptom resolution without ischemic complications.Conclusion: This case highlights the importance of early identification of ticagrelor-induced cutaneous hypersensitivity and demonstrates the safety of switching to an alternative P2Y12 inhibitor in the post-PCI setting.
No takes yet. Share an insight, caveat, or question.
Jadhav et al. (2026) conducted a case report in Acute coronary syndrome (n=1). Ticagrelor was evaluated on Cutaneous hypersensitivity reaction (pruritus, urticarial rash, and angioedema). Ticagrelor induced a cutaneous hypersensitivity reaction in a 56-year-old male post-PCI, which completely resolved within 48 hours after switching to prasugrel without ischemic complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: